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Abstract
The proteasome is a key regulator of cellular protein homeostasis and is a clinically validated anticancer target. The
immunoproteasome, a subtype of proteasome expressed mainly in hematopoietic cells, was initially recognized for its role
in antigen presentation during the immune response. Recently, the immunoproteasome has been implicated in several
disease conditions including cancer and autoimmune disorders, but many of the factors contributing to these pathological
processes remain unknown. In particular, the codon 60 polymorphism of the PSMB9 gene encoding the b1i
immunoproteasome catalytic subunit has been investigated in the context of a variety of diseases. Despite this, previous
studies have so far reported inconsistent findings regarding the impact of this polymorphism on proteasome activity. Thus,
we set out to investigate the impact of the PSMB9 codon 60 polymorphism on the expression and activity of the b1i
immunoproteasome subunit in a panel of human cancer cell lines. The b1i-selective fluorogenic substrate Acetyl-Pro-AlaLeu-7-amino-4-methylcoumarin was used to specifically measure b1i catalytic activity. Our results indicate that the codon
60 Arg/His polymorphism does not significantly alter the expression and activity of b1i among the cell lines tested.
Additionally, we also examined the expression of b1i in clinical samples from colon and pancreatic cancer patients. Our
immunohistochemical analyses showed that ,70% of clinical colon cancer samples and ,53% of pancreatic cancer samples
have detectable b1i expression. Taken together, our results indicate that the b1i subunit of the immunoproteasome is
frequently expressed in colon and pancreatic cancers but that the codon 60 genetic variants of b1i display similar catalytic
activities and are unlikely to contribute to the significant inter-cell-line and inter-individual variabilities in the
immunoproteasome activity.
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immunoproteasome may have important functions beyond the
adaptive immune response. For instance, the immunoproteasome
is found to be expressed in non-inflammed, immune-previleged
tissues (e.g. retina and brain [5,6]) and in the context of several
disease states (e.g. cancer, neurodegenerative diseases, autoimmune diseases, [3,7] and references therein). Despite these
observations, the biological significance of the immunoproteasome
in such disease states is not fully understood.
The b1i subunit of the immunoproteasome is encoded by the
PSMB9 gene located on chromosome 6. This gene harbors a
commonly occurring genetic R/H polymorphism at codon 60
(p.60R.H; c.179G.A; rs17587) with H allele frequencies of
1.1% to 34%, varying across ethnic groups ([8] and references
therein). Several investigations have reported potential associations
between codon 60 PSMB9 polymorphism status and increased
susceptibility to various diseases such as insulin-dependent diabetes
mellitus, rheumatoid arthritis and multiple sclerosis [8–16].
However, it is difficult to decipher from previous studies whether
the observed associations are directly related to the altered activity

Introduction
The proteasome is responsible for the degradation of targeted
proteins and is a key player in the maintenance of cellular protein
homeostasis and the regulation of cellular processes that are
essential in cancer development and progression [1,2]. The
immunoproteasome, an alternative form of the proteasome, is
found in cells of hematopoietic origin, but its expression can also
be induced under inflammatory and stress conditions in other cell
types [3]. The immunoproteasome is formed when the three types
of catalytic subunit found in the constitutive proteasome, b1 (Y,
PSMB6), b2 (Z, PSMB7) and b5 (X, PSMB5), are replaced by three
homologous immuno-subunits: b1i (LMP2, PSMB9), b2i (MECL1, PSMB10) and b5i (LMP7, PSMB8). Compared to the
constitutive proteasome, the immunoproteasome is found to have
slightly altered proteolytic specificities which are capable of
producing peptides more suitable for binding to the major
histocompatibility complex I molecules thus facilitating antigen
presentation [4]. However, recent studies indicate that the
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of the b1i subunit as a result of the R/H amino acid variation.
This is in part due to the inter-dependent nature of proteasome
subunits and the lack of appropriate molecular probes. A previous
investigation by Mishto et al. [17] examined more closely at the
impact of this polymorphism on proteasome activity in the aged
brain using the fluorogenic peptide substrate N-Succinyl-Leu-LeuVal-Tyr-AMC (Suc-LLVY-AMC). The results from this study
suggested that the H allele results in a decreased proteasome
activity in the aged brain [17]. However, since Suc-LLVY-AMC is
conventionally used to measure the overall chymotrypsin-like (CTL) proteolytic activity of the proteasome and thus can be
hydrolyzed by multiple subunits of both the immunoproteasome
and the constitutive proteasome, this decrease in the hydrolysis of
Suc-LLVY-AMC may not necessarily indicate changes in b1i
function. Furthermore, a subsequent study by the same group
using recombinant peptides mimicking endogenous substrates
indicated no differences in the substrate hydrolysis profiles
between the codon 60 genotypes [18].
Much of the discrepancy regarding the functional impact of the
PSMB9 codon 60 polymorphism arises from the lack of a tool to
specifically observe the function of the b1i subunit. In this regard,
Lin et al. [19] and Blackburn et al. [20] recently reported on the
development and application of the fluorogenic substrate AcetylPro-Ala-Leu-7-amino-4-methylcoumarin (Ac-PAL-AMC) which is
hydrolyzed selectively by b1i. This novel tool has made it possible
to assess the direct functional impact of PSMB9 codon 60
polymorphism on the b1i subunit. In our current study, we
investigated the expression of b1i in clinical colon and pancreatic
cancer tissues as well as in established human cancer cell lines.
Using the b1i-selective fluorogenic substrate Ac-PAL-AMC, we
also assessed the catalytic activity of b1i in multiple cancer cell
lines carrying different genotypes at codon 60. Our results
indicated that b1i is frequently expressed in colon and pancreatic
cancers, but the codon 60 PSMB9 polymorphism has no significant
impact on the catalytic activity of b1i expressed in multiple types of
cancer cell lines.

3,39-diaminobenzidine (DAB), and nuclei were counterstained
with hematoxylin. The specificity of immunoreactive signals was
verified by omitting either the primary or the secondary antibody.
The immunostained tissue microarray sections were analyzed by
an experienced pathologist (Dr. Eun Y. Lee). The intensity of
immunostaining was assigned on a scale of 0 to 2 or 3.

Determination of PSMB9 Polymorphic Status at Codon 60
The PSMB9 genotypes at codon 60 were initially determined
using standard PCR methods and DNA enzymatic digestions as
previously reported [24]. The amplicon covering the entire open
reading frame was subsequently cloned and analyzed by direct
sequencing to verify that the cell lines do not contain additional
genetic variations in the PSMB9 gene.

Immunoblotting Analysis
An equivalent amount of tissue or cell extracts were resolved in
polyacrylamide gels and transferred to PVDF membranes.
Membranes were blocked in 5% skim milk and probed with
anti-b1i (1:1000, Abcam) and anti-b-actin (1:1000, Novus)
antibodies. After washing, the blots were incubated with horseradish peroxidase-conjugated secondary antibodies. Bound antibodies were detected using an enhanced chemiluminescence
substrate (Pierce Biotechnology). In order to compare the relative
expression levels of b1i among multiple cell lines, serially diluted
H23 cell extracts were used as calibration standards and band
intensities were densitometrically quantified by using the Quantity
One software (Bio-Rad).

Proteasome Activity Assays
The catalytic activity of b1i was determined by monitoring the
hydrolysis rate of fluorescent 7-amino-4-methylcoumarine (AMC)
from Ac-PAL-AMC [20]. Briefly, purified proteasomal preparations or cell extracts containing equivalent total protein amount
(10 mg) were added to 96 well plates and adjusted to a final volume
of 50 ml using assay buffer (20 mM Tris/Cl, 0.5 mM EDTA,
pH 8.0). The reaction was initiated by adding Ac-PAL-AMC
(100 mM) and the fluorescence of liberated AMC was monitored
for 90 min using a SpectraMax M5 plate reader (Molecular
Devices, excitation 360 nm and emission 460 nm). In order to
verify that substrate hydrolysis is mediated by b1i, additional sets
of cell extracts or purified proteasomal preparations were pretreated with proteasome inhibitors UK101 or epoxomicin for 1 h,
after which fluorescent signals were monitored. In separate
experiments, the hydrolysis of Suc-LLVY-AMC (100 mM) was
monitored to assess the overall CT-L proteolytic activity.

Materials and Methods
Cell Culture and Reagents
Established cell lines derived from various types of human
cancers (colon, HCT-8, DLD-1, HCT-116, SW480; lung, H23,
H358, H460, H727, H1299; prostate, PC-3, DU145; pancreas,
BxPC-3, PANC-1, AsPC1; breast, MCF-7, HS578T, MDA-MB231) were purchased from the American Type Culture Collection
(ATCC) and maintained under the recommended conditions. The
fluorogenic substrates Suc-LLVY-AMC and Ac-PAL-AMC were
custom-synthesized following the standard peptide synthesis
strategy. Proteasome inhibitors UK-101 and epoxomicin were
synthesized and purified as reported previously [21,22]. Purified
20 S constitutive proteasome and immunoproteasome were
purchased from Boston Biochem.

Statistical Analysis
Values from data were expressed as means with standard
deviations. A comparison between the groups was performed using
the Student’s t-test and p,0.05 was considered significant.

Immunohistochemical Analysis

Results

Tissue microarrays containing de-identified, archival cases of
human colon and pancreatic cancer tissue specimens were
obtained from US Biomax. The use of de-identified tissue array
samples from a commercial source for the current study was
deemed to be exempt from the Human Subject Regulation by the
Institutional Review Board. A streptavidin-biotin-immunoperoxidase assay was performed after the antigen retrieval procedure
(citrate buffer, pH 6) using a monoclonal antibody against b1i
(1:100 dilution, Enzo Life Sciences) according to the previously
reported protocol [23]. Immune reaction was visualized using
PLOS ONE | www.plosone.org

Frequent Expression of b1i in Colon and Pancreatic
Cancer Tissues
In assessing the expression of b1i in colon cancer, we first
utilized four pairs of colon cancer and nonmalignant adjacent
colonic tissues from matching donors. Our immunoblotting
analyses indicated that b1i levels were highly elevated in all four
clinical colon cancer tissues compared to the paired nonmalignant
colonic tissues (Figure 1A). To further evaluate the frequency of
b1i expression in colon cancer, we performed immunohistochem2
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Figure 1. b1i is frequently expressed in colorectal and pancreatic cancer tissues. (a) Immunoblotting analysis for b1i using protein lysates
prepared from nonmalignant (N) and cancerous (T) colonic tissues from the same donors (n = 4 pairs). b-actin was used as a loading control. The band
intensities for b1i and b-actin were densitometrically analyzed and used to obtain the relative b1i expression normalized to b-actin levels. (b)
Immunohistochemical staining for b1i using a tumor array containing 153 evaluable tumor colon tissue specimens. The intensities of b1i positive
staining were evaluated on a scale of 0 to 3. Approximately 70% (46 specimens had intensity of grade 1, 38 with grade 2, and 8 with grade 3, out of
153 total tumor specimens) of colorectal tissues have positive (the staining intensity $1) b1i staining. (c) Immunohistochemical staining for b1i using
a tumor array containing 43 evaluable tumor pancreatic tissue specimens. The intensities of b1i positive staining were evaluated on a scale of 0 to 2.
Approximately 53% (9 specimens with intensity grade 1, and 14 with grade 2, out of 43 total tumor specimens) of pancreatic cancer tissues had $1
b1i staining intensity.
doi:10.1371/journal.pone.0073732.g001
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Figure 2. Ac-PAL-AMC is hydrolyzed selectively by b1i. (a) Chemical structure of Ac-PAL-AMC. (b) Ac-PAL-AMC hydrolysis over time by purified
constitutive proteasome (cross), purified immunoproteasome (closed circle), or purified immunoproteasome pre-treated with UK101 (open square). A
linear increase was seen in immunoproteasome-containing wells only. (c) The rate of hydrolysis of Ac-PAL-AMC or Suc-LLVY-AMC in the presence of
Panc-1 cell extract (10 mg). Hydrolysis of Ac-PAL-AMC was almost completely inhibited by UK101 pre-treatment (10 mM). Hydrolysis of Suc-LLVY-AMC
was partially inhibited by UK-101 pre-treatment. Epoxomicin (Epx, 10 mM), a broadly-acting proteasome inhibitor, was used as a positive control.
doi:10.1371/journal.pone.0073732.g002

ical analyses on a tumor array containing 153 evaluable colon
cancer specimens of all clinical stages. The intensity of b1i staining
was evaluated on a scale of 0 to 3 and our results indicated that the
majority (approximately 70%, n = 107 out of 153 total specimens)
of colon cancer tissues were positive (the staining intensity $1) for
b1i staining (Figure 1B). Similar analyses were performed using a
tumor array containing 43 evaluable pancreatic cancer specimens
of all clinical stages. Due to the limited sample size, the intensity of
b1i staining was evaluated on a scale of 0 to 2 and our results
indicated that approximately 53% (n = 23 out of 43 total
specimens) of pancreatic cancer tissues had positive (the staining
intensity $1) b1i staining (Figure 1C). For both tissue arrays, we
assessed whether there is any association between the b1i
expression and available clinicopathologic factors (e.g. gender
and tumor grade). However, the results did not reveal any
apparent associations.

Catalytic Activity of b1i in a Panel of Human Cancer Cell
Lines Carrying Different Codon 60 Polymorphic Variants
Previously, Blackburn et al. [20] reported that Ac-PAL-AMC
(Figure 2A) can be used as a selective probe for measuring the
catalytic activity of b1i. Prior to the use of Ac-PAL-AMC in our
study, we further verified that the hydrolysis of Ac-PAL-AMC was
selectively mediated by b1i using purified preparations of
immunoproteasome and constitutive proteasome. Indeed, AcPAL-AMC was readily hydrolyzed by the immunoproteasome,
but not by the constitutive proteasome (Figure 2B). Pretreatment
with UK101, a b1i-selective proteasome inhibitor [21], completely
inhibited Ac-PAL-AMC hydrolysis, further validating Ac-PALAMC as a b1i-selecitve probe (Figure 2B). Similarly, approximately 90% of hydrolysis of Ac-PAL-AMC was inhibited in Panc1 cell extracts by UK-101 pre-treatment (Figure 2C). In contrast,
the hydrolysis of Suc-LLVY-AMC was only partially blocked by
UK101 pretreatment in Panc-1 extracts, suggesting that SucLLVY-AMC is hydrolyzed by proteasome subunits other than b1i
(i.e. b5 or b5i) (Figure 2C).

Figure 3. The catalytic activity of b1i is not affected by the PSMB9 codon 60 polymorphisms. (a) The catalytic activity of b1i measured by
rate of hydrolysis of Ac-PAL-AMC in human cancer cell lines with H/H or R/H genotype (blank bars) and R/R genotype (filled bars). Variable activity
was observed among cell lines. (b) Rate of Ac-PAL-AMC hydrolysis in cell lines with H/H or R/H genotype (open circles) or R/R genotype (closed
squares). Rate of hydrolysis did not show any statistically significant difference between H+ and H- cell lines.
doi:10.1371/journal.pone.0073732.g003
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Figure 4. Determination b1i expression levels across multiple human cancer cell lines. An equivalent amount (10 mg) of cell extracts were
subjected to immunoblotting with an antibody to b1i along with serially diluted H23 cell extracts (calibration standards). Densitometric analyses of
band intensities were performed to quantify relative expression levels of b1i. Cell lines expression high levels of b1i are shown in (A) and cell lines
with low expression of b1i are shown in (B).
doi:10.1371/journal.pone.0073732.g004

Following the validation of Ac-PAL-AMC as a b1i-selective
probe, we then assessed the b1i activity in a panel of human
cancer cell lines. These cell lines were screened for their PSMB9
genotypes at codon 60 (n = 6 for those carrying HH or HR
genotype; n = 11 for those carrying RR genotype) and verified not
to have any additional variations in the PSMB9 gene by direct
sequencing (Table S1). Our results indicated that the catalytic
activities of b1i assessed by the hydrolysis rate of Ac-PAL-AMC
substantially vary among these cell lines, however these differences
do not seem to be associated with the codon 60 polymorphic status
(Figure 3).

A comparison of cell lines with the H-allele to those that lack the
H-allele showed no statistically significant differences in b1i
expression (Figure 5A). Instead, we found a highly significant
correlation between the catalytic activity b1i and its expression
level (Figure 5B, r2 = 0.86, p,0.0001, individual values are
included in Table S1). These findings suggested that the differing
expression levels of b1i likely account for the majority of variability
observed in the b1i activity across different cell lines.

Discussion
In our current study, we investigated the impact of the PSMB9
codon 60 polymorphisms on the b1i subunit of the immunoproteasome expressed in multiple cancer cell lines using a recently
reported b1i activity probe, Ac-PAL-AMC. Our results indicated
that the codon 60 polymorphism has no major impact on the
expression levels or catalytic activities of b1i in the panel of human
cancer cell lines tested. These results are different from previous
findings which indicated that brain tissue from aged individuals
carrying the codon 60 H allele had decreased proteasome activity

b1i Expression in Human Cancer Cell Lines Carrying
Different Codon 60 Polymorphic Variants
As a next step, we examined whether the b1i expression levels
are influenced by the codon 60 polymorphic status in the tested
cancer cell lines. In order to quantify b1i protein levels, which
display substantial variability across different cell lines, we used
serially diluted H23 cell extracts as calibration standards (Figure 4).
PLOS ONE | www.plosone.org
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Figure 5. The expression levels of b1i are not affected by the PSMB9 codon 60 polymorphisms, but associated with the b1i activity.
(a) b1i expression in cell lines with H/H or R/H (open circle) and R/R genotypes (closed square). b1i expression did not show statistically significant
difference between H+ and H- cell lines. (b) Correlation of Ac-PAL-AMC hydrolysis with b1i expression in all cell lines tested. A highly significant
correlation was noted between the expression levels of b1i and its catalytic activity (R2 = 0.86, p,0.0001).
doi:10.1371/journal.pone.0073732.g005

compared to tissue from those who did not carry the codon 60 H
allele [17]. A possible reason for these apparent discrepancies may
be related to the different substrates used to assess proteolytic
activity. The fluorogenic substrate Suc-LLVY-AMC used by
Mishto et al. [17] is commonly used to measure the overall
chymotrypsin-like activity of the proteasome. However, since this
substrate can be hydrolyzed by both the immunoproteasome (b1i
and b5i) and the constitutive proteasome (b5) [25], the results
obtained using Suc-LLVY-AMC cannot tease out the direct
contribution of the b1i genetic polymorphism. Our current results
were obtained using the recently reported substrate Ac-PAL-AMC
that is selectively cleaved by the b1i subunit (Figure 2) [20]. Our
findings are consistent with the previous report that the PSMB9
codon 60 polymorphism had no impact on the degradation
profiles of a 28-mer peptide (Kloe 258) and a recombinant form of
IkBa, a key regulator of classical NF-kB pathway and well-known
proteasome substrate [18]. Although we cannot completely rule
out the possibility that the impact of the codon 60 polymorphism
may vary depending on the substrate and disease types, the results
from the current study and others suggest that the codon 60
polymorphism will not likely contribute to inter-individual
variability in b1i catalytic activity levels.
With the remarkable clinical successes of bortezomib and
carfilzomib in treating multiple myeloma and other hematological
malignancies, the proteasome is now recognized as an important
chemotherapeutic target. However, undesirable toxicities limit the
broad use of the currently available proteasome-targeting drugs.
To overcome these limitations, the immunoproteasome, an
alternative form of the constitutive proteasome, has been explored
as an alternative therapeutic target. Such efforts have yielded
promising immunoproteasome-targeting compounds with anticancer efficacy and improved toxicity profiles [7,23,26,27]. In
exploring immunoproteasome-targeting approaches for cancer
therapy, it is important to consider the immunoproteasome
expression across different cancer types. While the immunoproteasome is known to be upregulated in hematological malignancies, the expression of the immunoproteasome in solid cancer has
not been thoroughly examined. In the current study, we report
that the b1i subunit is frequently expressed in clinical tissue
specimens from colon and pancreatic cancers as well as a panel of
human cancer cell lines derived from colon, lung, prostate and
PLOS ONE | www.plosone.org

breast tissues. Although similar findings have been reported by our
group and others [21,23,28,29], our current study provides more
robust information regarding the expression of b1i in the majority
of clinical colon and pancreatic cancer tissues tested. It should be
noted that the downregulation of immunoproteasome subunits has
also been reported in some types of cancer [30–34] and it is
possible that the expression status of the immunoproteasome may
be dependent on disease types and their pathogenic mechanisms.
On the other hand, it should be noted that our results on the
frequencies of b1i polymorphisms of cancer cell lines derived from
different organs are not necessarily reflective of those among these
cancer types. This is in part due to the small sample size and the
experimental design of our current study. In particular, our
experimental design involved the exclusion of several cell lines
harboring additional polymorphisms in the genes encoding b1i
and/or other immunoproteasome subunits such as b5i in order to
minimize potential compounding factors. Our results suggest that
the codon 60 polymorphisms are not likely to be responsible for
the observed variability in the b1i expression/activity among the
tested cell lines. In further validating our findings, it may be
important to employ a larger sample size of cancer cell lines or
clinical samples derived from the same organs, perhaps comparison of samples with comparable b1i expression levels. Additionally, genetic association studies examining the b1i polymorphism
at codon 60 in the context of cancer development and progression
are also warranted.
In conclusion, our results demonstrate that the b1i subunit of
the immunoproteasome is frequently expressed in colon and
pancreatic cancers and possibly in other types of solid cancers. In
addition, the genetic polymorphism at codon 60 appears to have
no major impact on the expression and catalytic activity of b1i in
cancer cells. Taken together, these findings may provide useful
insights for the development of immunoproteasome-targeting anticancer agents. Additionally, these results exclude codon 60
polymorphic status as a potential factor contributing to variable
sensitivity to immunoproteasome inhibitors targeting b1i.
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